Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $547,933.70 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 1,510 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the transaction, the executive vice president owned 22,511 shares in the company, valued at $8,168,566.57. This trade represents a 6.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $359.27 on Friday. The business’s fifty day moving average is $418.74 and its 200 day moving average is $421.35. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The stock has a market cap of $47.46 billion, a price-to-earnings ratio of 1,496.96 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Morgan Stanley lifted their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a report on Monday, October 6th. Piper Sandler reissued an “overweight” rating and set a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Royal Bank Of Canada lifted their target price on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. Jefferies Financial Group cut their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Finally, Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $490.96.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ALNY. Thematics Asset Management bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $1,995,000. Teacher Retirement System of Texas lifted its position in shares of Alnylam Pharmaceuticals by 3.2% during the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock valued at $11,872,000 after buying an additional 1,123 shares during the last quarter. Generali Asset Management SPA SGR boosted its holdings in shares of Alnylam Pharmaceuticals by 6,368.0% in the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 3,184 shares in the last quarter. Investment Management Corp of Ontario grew its position in shares of Alnylam Pharmaceuticals by 35.4% in the 2nd quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock worth $10,279,000 after buying an additional 8,244 shares during the last quarter. Finally, Congress Asset Management Co. bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $54,173,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.